Latest press releases Feb 02 2023 MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa Dec 14 2022 MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis Nov 14 2022 MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update View All News View All Press Releases + Upcoming events Feb 14 - Feb 16 2023 SVB Securities Global Biopharma Conference Mar 6 - Mar 8 2023 Cowen 43rd Annual Healthcare Conference Mar 17 - Mar 21 2023 Annual Meeting of the American Academy of Dermatology (AAD) 2023 View All Events View All Events + Corporate presentations Corporate presentation - January 2023 View All Presentations View All Presentations + IR contact details Dr. Atif Khan, Director of Strategic Planning and Projects e: ir@moonlaketx.com
Feb 02 2023 MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa
Dec 14 2022 MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
Nov 14 2022 MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
MoonLake
MoonLake
